|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/21 | (2006.01) |
| A61K 38/37 | (2006.01) | ||
| A61K 39/00 | (2006.01) | ||
| A61K 47/68 | (2017.01) | ||
| C12Q 1/68 | (2018.01) | ||
| C07K 14/755 | (2006.01) | ||
| C12Q 1/6883 | (2018.01) | ||
| A61P 37/06 | (2006.01) |
| (11) | Number of the document | 3453402 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18183272.6 |
| Date of filing the European patent application | 2013-01-12 | |
| (97) | Date of publication of the European application | 2019-03-13 |
| (45) | Date of publication and mention of the grant of the patent | 2021-07-21 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201261586103 P | 2012-01-12 | US | |
| 201261668961 P | 2012-07-06 | US |
| (72) |
JIANG, Haiyan , US
LIU, Tongyao , US
KRISHNAMOORTHY, Sriram , US
JOSEPHSON, Neil , US
GLENN, Pierce , US
|
| (73) |
Bioverativ Therapeutics Inc. ,
225 Second Avenue, Waltham MA 02451,
US
Puget Sound Blood Center , 921 Terry Avenue, Seattle, Washington 98104-1256, US |
| (54) | REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY |
| REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY |